Bristol-Myers Squibb: fresh buy signal in a strong sector, but the context calls for caution

Bristol-Myers Squibb opens a fresh buy signal in week 1, with signal strength at 50 out of 100 and the Health Care sector in positive regime. Our model flags the situation as not recommended for new positions: the stock is operating near recent highs with a trapped range, conditions that make opening a new long elevated-risk according to our analysis.